Leadiant Biosciences, Inc.
Quick facts
Phase 3 pipeline
- Adagen · Other
- EZN-2279 · Cardiovascular
EZN-2279 is an antisense oligonucleotide that inhibits apolipoprotein C-III (apoC-III) expression to reduce triglycerides and improve lipid metabolism.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Leadiant Biosciences, Inc.
What is Leadiant Biosciences, Inc.'s pipeline?
Leadiant Biosciences, Inc. has 2 drugs in Phase 3, 0 in Phase 2, 1 in Phase 1. Late-stage candidates include Adagen, EZN-2279.
Related
- Sector hub: All tracked pharma companies